Abstract
Hypertension represents the most common cardiovascular risk factor, affecting more than 25% of the adult population in developed societies. Although beta-blockers have been previously shown to effectively reduce blood pressure and have been used for hypertension treatment for over 40 years, their effect on cardiovascular morbidity and mortality in hypertensive patients remains controversial and their use in uncomplicated hypertension is currently still under debate. According to the previous recommendations beta-blockers should not be preferred as first-line therapy in hypertension patients. This review summarizes the current knowledge on application of beta-blockers in patients with hypertension and discusses the most recent guidelines of the European Society of Hypertension (2009) on beta-blockers applications.
Keywords: Hypertension, antihypertensive treatment, beta-blocker, cardiovascular risk, beta-blockers, blood pressure, carteolol, carvedilol, labetalol, nadolol, penbutolol, pindolol, propranolol, timolol, atenolol, betaxolol, bisoprolol, metoprolol, nebivolol, diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, National Institute for Health and Clinical Excellence, ESH/ESC 2007, European Lacidipine Study on Atherosclerosis, Losar-tan Intervention For Endpoint, Anglo-Scandinavian Cardiac Outcomes Trial, Blood Pressure Low-ering Arm, International Verapamil-Trandolapril Study, Metoprolol Atherosclerosis Prevention in Hypertension, ACE inhibitors, Conduit Artery Function Evaluation, Canadian Hypertension Education Program, coronary artery disease CHF, congestive heart failure
Current Vascular Pharmacology
Title: Current Place of Beta-Blockers in the Treatment of Hypertension
Volume: 8 Issue: 6
Author(s): Agata Bielecka-Dabrowa, Wilbert S. Aronow, Jacek Rysz and Maciej Banach
Affiliation:
Keywords: Hypertension, antihypertensive treatment, beta-blocker, cardiovascular risk, beta-blockers, blood pressure, carteolol, carvedilol, labetalol, nadolol, penbutolol, pindolol, propranolol, timolol, atenolol, betaxolol, bisoprolol, metoprolol, nebivolol, diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, National Institute for Health and Clinical Excellence, ESH/ESC 2007, European Lacidipine Study on Atherosclerosis, Losar-tan Intervention For Endpoint, Anglo-Scandinavian Cardiac Outcomes Trial, Blood Pressure Low-ering Arm, International Verapamil-Trandolapril Study, Metoprolol Atherosclerosis Prevention in Hypertension, ACE inhibitors, Conduit Artery Function Evaluation, Canadian Hypertension Education Program, coronary artery disease CHF, congestive heart failure
Abstract: Hypertension represents the most common cardiovascular risk factor, affecting more than 25% of the adult population in developed societies. Although beta-blockers have been previously shown to effectively reduce blood pressure and have been used for hypertension treatment for over 40 years, their effect on cardiovascular morbidity and mortality in hypertensive patients remains controversial and their use in uncomplicated hypertension is currently still under debate. According to the previous recommendations beta-blockers should not be preferred as first-line therapy in hypertension patients. This review summarizes the current knowledge on application of beta-blockers in patients with hypertension and discusses the most recent guidelines of the European Society of Hypertension (2009) on beta-blockers applications.
Export Options
About this article
Cite this article as:
Bielecka-Dabrowa Agata, S. Aronow Wilbert, Rysz Jacek and Banach Maciej, Current Place of Beta-Blockers in the Treatment of Hypertension, Current Vascular Pharmacology 2010; 8 (6) . https://dx.doi.org/10.2174/157016110793563861
DOI https://dx.doi.org/10.2174/157016110793563861 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Interaction Between Platelets and Cytokines - A Possible Role in the Pathogenesis of Preeclampsia
Vascular Disease Prevention (Discontinued) Food Applications for Flaxseed and its Components: Products and Processing
Recent Patents on Food, Nutrition & Agriculture Targeting Kruppel-Like Factor 5 (KLF5) for Cancer Therapy
Current Topics in Medicinal Chemistry Diabetic Patients with Psychiatric Illness
Current Diabetes Reviews Isoform-Selective PI3K Inhibitors for Various Diseases
Current Topics in Medicinal Chemistry Emerging Risk Factors for Dementia: The Role of Blood Pressure Variability
CNS & Neurological Disorders - Drug Targets Diabetes and Cardiovascular Disease Following Kidney Transplantation
Current Diabetes Reviews Recent Patents on Eggshell: Shell and Membrane Applications
Recent Patents on Food, Nutrition & Agriculture Heart Failure in East Asia
Current Cardiology Reviews Hypoglycaemia and Cardiovascular Disease Risk in Patients with Diabetes
Current Pharmaceutical Design Nigella Sativa Improve Redox Homeostasis in Heart and Aorta of Diabetic Rat
Current Nutrition & Food Science Cyclosporin and Organ Specific Toxicity: Clinical Aspects, Pharmacogenetics and Perspectives
Current Clinical Pharmacology Potential Role of microRNAs in Cardiovascular Disease: Are They up to Their Hype?
Current Cardiology Reviews Adverse Drug Reactions Amongst Adult Patients Admitted in Lagos State University Teaching Hospital Lagos, Nigeria
Current Drug Safety Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment
Current Pharmaceutical Design Medullary Thyroid Cancer: New Targeted Molecular Therapies
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Understanding eNOS for Pharmacological Modulation of Endothelial Function: A Translational View
Current Pharmaceutical Design Orai1 and Transient Receptor Potential Channels as Novel Molecular Targets to Impair Tumor Neovascularization in Renal Cell Carcinoma and other Malignancies
Anti-Cancer Agents in Medicinal Chemistry Association of Soluble Adhesion Molecule and C-Reactive Protein Levels with Silent Brain Infarction in Patients with and Without Type 2 Diabetes
Current Neurovascular Research Pharmacological Approaches in the Treatment of Atrial Fibrillation
Current Medicinal Chemistry